Financial Performance - The company's operating revenue for Q3 2022 was ¥1,686,550,783.48, representing a year-over-year increase of 6.66%[2] - The net profit attributable to shareholders for the same period was ¥124,972,562.07, with a year-over-year increase of 1.35%[2] - Net profit for Q3 2022 was ¥879,417,134.80, compared to ¥757,299,542.49 in Q3 2021, reflecting a 16.1% increase[18] - Earnings per share for Q3 2022 were ¥1.22, up from ¥1.06 in Q3 2021[19] - The company reported a total profit of ¥1,012,709,040.25 for Q3 2022, up from ¥928,998,947.93 in Q3 2021[18] Research and Development - Research and development expenses totaled ¥422,240,475.69 in Q3 2022, marking a significant increase of 45.71% compared to the previous year[4] - The ratio of R&D expenses to operating revenue was 25.04%, an increase of 6.71 percentage points year-over-year[4] - Research and development expenses for the first three quarters of 2022 totaled ¥867,972,581.95, an increase from ¥734,116,099.21 in 2021, indicating a focus on innovation[17] Assets and Liabilities - Total assets at the end of Q3 2022 reached ¥22,176,347,625.49, reflecting a substantial increase of 114.02% from the end of the previous year[4] - The company's total liabilities were RMB 5.50 billion, slightly up from RMB 5.33 billion, indicating a growth of about 3.2%[15] - The company's total liabilities and shareholders' equity increased to ¥22,176,347,625.49, compared to ¥10,361,883,193.35 in the previous year[16] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥864,422,041.45, indicating a significant cash outflow[4] - The cash inflow from operating activities for Q3 2022 was CNY 5,819,203,236.19, an increase from CNY 4,984,704,378.58 in Q3 2021, representing a growth of approximately 16.7%[20] - The net cash outflow from investment activities was CNY -1,596,647,075.84, compared to CNY -739,429,635.74 in the same period last year, indicating a decline in investment cash flow[21] - The cash inflow from financing activities was CNY 10,797,240,000.00, significantly higher than CNY 65,882,733.36 in Q3 2021, showing a substantial increase in financing[21] Equity and Shareholder Information - Shareholders' equity attributable to the parent company was ¥16,703,373,359.03, up 231.59% compared to the previous year[4] - The company's equity increased significantly, with paid-in capital rising to RMB 824.16 million from RMB 724.16 million, reflecting a growth of approximately 13.8%[15] Other Financial Metrics - The basic earnings per share for Q3 2022 was ¥0.16, a decrease of 2.95% year-over-year[4] - The diluted earnings per share for the same period was also ¥0.16, with a similar decrease of 2.95% year-over-year[4] - Other comprehensive income after tax for Q3 2022 was ¥12,844,348.90, compared to a loss of ¥7,086,245.76 in Q3 2021[19] - The company experienced a decrease in tax expenses, which were ¥133,291,905.45 in Q3 2022, down from ¥171,699,405.44 in Q3 2021[18] Inventory and Receivables - Accounts receivable rose to RMB 1.83 billion, compared to RMB 1.05 billion in the same period last year, representing a growth of approximately 74.4%[14] - Inventory levels increased to RMB 3.28 billion, up from RMB 2.21 billion, marking a rise of around 48.5%[14] Government Support - The company reported government subsidies recognized in the current period amounting to ¥104,410,819.32, contributing positively to the financial results[5] Market Activity - The company has not reported any significant new product launches or technological advancements during this quarter[12] - There are no indications of market expansion or mergers and acquisitions activities reported in this quarter[12]
联影医疗(688271) - 2022 Q3 - 季度财报